



## **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA251)**

### **NICE GUIDANCE ISSUED APRIL 2012**

(Refer to NICE website for full guidance on NICE recommendations,  
including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

### **Dasatinib (Sprycel<sup>®</sup>▼)**

**Submission by: Bristol-Myers Squibb**

**Advice No: 1211 – September 2011**

### **Recommendation of AWMSG**

**Dasatinib (Sprycel<sup>®</sup>▼) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia in the chronic phase is not recommended for use within NHS Wales. The case for cost effectiveness has not been proven.**

#### **Additional notes:**

People who are currently being treated with Dasatinib (Sprycel<sup>®</sup>▼) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: